

NOVO NORDISK A S
Form IRANNOTICE
February 10, 2016

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

February 10, 2016

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Dear Sirs,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on February 10, 2016.

Sincerely,

/s/ Lars Rebien Sørensen

/s/ Jesper Brandgaard

Lars Rebien Sørensen

Jesper Brandgaard

President and Chief Executive Officer Executive Vice President and

Chief Financial Officer

Telephone: Internet:

Novo Allé
Novo Nordisk A/S DK-2880 Bagsværd
Denmark

+45 4444 8888 novonordisk.com

Telefax: CVR Number:

+45 4444 6626 24256790